Updated guidelines for the management of people with chronic hepatitis C have been released by GESA in conjunction with groups including the Australasian Society for Infectious Diseases, the Australasian Hepatology Association and Hepatitis Australia.

The guidelines cover models of care, screening and diagnosis, pre-treatment assessment, treatment and monitoring and post-treatment follow up.

The new position statement also includes guidance on special populations such as decompensated liver disease, after liver transplantation, HIV or HBV co-infection and people with renal impairment.

Important updates include:

1. PBS listing of glecaprevir plus pibrentasvir (Maviret), the first pan-genotypic treatment option for people with renal impairment, is not renally excreted.
2. TGA approval of sofosbuvir plus velpatasvir plus voxilaprevir (Vosevi). This is a pan-genotypic regimen of three DAAs that is expected to be listed on the PBS in 2019 for the treatment of people who did not respond to a first-line DAA regimen.
3. Simplified recommendations for on-treatment monitoring during DAA therapy.
4. New recommendations for the management of non-responders to DAA therapy.
5. Changed recommendations for the management of HCV in the setting of renal impairment

The new HCV consensus statement is available at gesa.org.au.